BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute for Bioengineering of Catalonia - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute for Bioengineering of Catalonia
X-ORIGINAL-URL:https://ibecbarcelona.eu
X-WR-CALDESC:Events for Institute for Bioengineering of Catalonia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190301T100000
DTEND;TZID=Europe/Madrid:20190301T120000
DTSTAMP:20260425T121949
CREATED:20190220T155437Z
LAST-MODIFIED:20190220T155437Z
UID:65718-1551434400-1551441600@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Irene Marco
DESCRIPTION:Hyperpolarised magnetic resonance for real-time\, in situ monitoring of cell metabolism\nIrene Marco\, Biosensors for bioengineering – IBEC  \nThere is a clinical need for non-invasive and reliable markers to diagnose\, stage and evaluate treatment response in many diseases such as cancer or non-alcoholic fatty liver disease.\nMagnetic resonance (MR) methods now have the potential to revolutionise in the identification of such biomarkers in real time. Spectroscopic identification and quantitation of metabolites via carbon-13 chemical shifts can be combined with imaging (MRI) to simultaneously probe spatial (biodistribution) and temporal (kinetics) aspects of metabolism in vivo. These capabilities are enabled by so-called hyperpolarised (HP) MR techniques\, including Dynamic Nuclear Polarisation (DNP)\, which can transiently boost the carbon-13 MR signals by several orders of magnitude\, compared to traditional methods. DNP enables real-time measurement of enzymatic reactions in cell suspensions and in vivo. Multiple HP 13C-labelled substrates have provided insights in several metabolic pathways\, including glycolysis\, the pentose-phosphate pathway and the cellular redox state. I will present the potential of DNP to study metabolism in cell suspensions\, tissue ex vivo and animals in vivo\, as well as tap on the advances into the clinical translation of the technique. Also\, I will talk about how we intend to implement HP MR to monitor metabolism in organs-in-chips in the lab of Javier Ramón (IBEC).
URL:https://ibecbarcelona.eu/event/ibec-seminar-irene-marco/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190301T100000
DTEND;TZID=Europe/Madrid:20190301T120000
DTSTAMP:20260425T121949
CREATED:20190220T155437Z
LAST-MODIFIED:20190220T155437Z
UID:96402-1551434400-1551441600@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Irene Marco
DESCRIPTION:Hyperpolarised magnetic resonance for real-time\, in situ monitoring of cell metabolism\nIrene Marco\, Biosensors for bioengineering – IBEC  \nThere is a clinical need for non-invasive and reliable markers to diagnose\, stage and evaluate treatment response in many diseases such as cancer or non-alcoholic fatty liver disease.\nMagnetic resonance (MR) methods now have the potential to revolutionise in the identification of such biomarkers in real time. Spectroscopic identification and quantitation of metabolites via carbon-13 chemical shifts can be combined with imaging (MRI) to simultaneously probe spatial (biodistribution) and temporal (kinetics) aspects of metabolism in vivo. These capabilities are enabled by so-called hyperpolarised (HP) MR techniques\, including Dynamic Nuclear Polarisation (DNP)\, which can transiently boost the carbon-13 MR signals by several orders of magnitude\, compared to traditional methods. DNP enables real-time measurement of enzymatic reactions in cell suspensions and in vivo. Multiple HP 13C-labelled substrates have provided insights in several metabolic pathways\, including glycolysis\, the pentose-phosphate pathway and the cellular redox state. I will present the potential of DNP to study metabolism in cell suspensions\, tissue ex vivo and animals in vivo\, as well as tap on the advances into the clinical translation of the technique. Also\, I will talk about how we intend to implement HP MR to monitor metabolism in organs-in-chips in the lab of Javier Ramón (IBEC).
URL:https://ibecbarcelona.eu/event/ibec-seminar-irene-marco-3/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190315T100000
DTEND;TZID=Europe/Madrid:20190315T120000
DTSTAMP:20260425T121949
CREATED:20190306T164913Z
LAST-MODIFIED:20190306T165355Z
UID:65852-1552644000-1552651200@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Paul Wright
DESCRIPTION:Nanosafety research addressing public health concerns about metal oxide nanoparticles\nPaul Wright\, Head of RMIT Nanosafety Research Group – RMIT University \nPaul Wright is Australia’s foremost expert in nanotoxicology and nanosafety\, and founding co-ordinator of the Asia Nano Safe and NanoSafe Australia research networks. He is the toxicologist at RMIT University’s School of Health and Biomedical Sciences\, at Bundoora in Melbourne\, Australia. He heads RMIT’s Nanosafety Research Group and led RMIT’s large contribution to the Australian Consortium for the OECD’s recent nanosafety testing program. He is nanosafety advisor to the Australian Nanotechnology Network (ANN)\, and has directly advised several Australian Federal and state government authorities and committees on nanosafety issues. Paul is a Fellow of International Union of Pure and Applied Chemistry (IUPAC) and formerly an elected director of the Executive Committee of International Union of Toxicology (IUTOX).
URL:https://ibecbarcelona.eu/event/ibec-seminar-paul-wright/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar,Joint seminar / workshop / symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190315T100000
DTEND;TZID=Europe/Madrid:20190315T120000
DTSTAMP:20260425T121949
CREATED:20190306T164913Z
LAST-MODIFIED:20190306T164913Z
UID:96404-1552644000-1552651200@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Paul Wright
DESCRIPTION:Nanosafety research addressing public health concerns about metal oxide nanoparticles\nPaul Wright\, Head of RMIT Nanosafety Research Group – RMIT University \nPaul Wright is Australia’s foremost expert in nanotoxicology and nanosafety\, and founding co-ordinator of the Asia Nano Safe and NanoSafe Australia research networks. He is the toxicologist at RMIT University’s School of Health and Biomedical Sciences\, at Bundoora in Melbourne\, Australia. He heads RMIT’s Nanosafety Research Group and led RMIT’s large contribution to the Australian Consortium for the OECD’s recent nanosafety testing program. He is nanosafety advisor to the Australian Nanotechnology Network (ANN)\, and has directly advised several Australian Federal and state government authorities and committees on nanosafety issues. Paul is a Fellow of International Union of Pure and Applied Chemistry (IUPAC) and formerly an elected director of the Executive Committee of International Union of Toxicology (IUTOX).
URL:https://ibecbarcelona.eu/event/ibec-seminar-paul-wright-2/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar,Joint seminar / workshop / symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190322T100000
DTEND;TZID=Europe/Madrid:20190322T120000
DTSTAMP:20260425T121949
CREATED:20190319T101144Z
LAST-MODIFIED:20190319T101144Z
UID:96419-1553248800-1553256000@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Silvia Muro
DESCRIPTION:Spread the word!\nNest Friday we are glad to present to all those who are part of the IBEC community the IBEC FASTER FUTURE programme\, an initiative to accelerate our research in a collaborative way together with patients’ associations and hospitals. Everyone can be involved and we will comment the different ways to contribute to Faster Future. \nThis year\, we have added a new project led by Dr. Silvia Muro\, responsible for the Targeted therapeutics and nanodevices group\, related to Parkinson’s disease\, that affects millions of people around the world. \nIn this presentation\, Silvia Muro will talk about Enabling Delivery of Therapeutics Across the Blood-Brain Barrier for Treatment of Neurodegenerative Diseases. \nGet involved\, we count on you!\nEnabling Delivery of Therapeutics Across the Blood-Brain Barrier for Treatment of Neurodegenerative Diseases\nSilvia Muro\, IBEC Group Leader Targeted therapeutics and nanodevices / ICREA Research Professor\n \nAccessing the brain is key to study its function and pathology\, and for diagnostic and therapeutic purposes. Yet\, this remains a formidable challenge due to the blood-brain barrier (BBB). To overcome this obstacle\, new nanovehicles are being designed to cross this interface\, without much translational success. A prime obstacle is the lack of knowledge on the biological regulation of these devices\, as most efforts have been devoted to controling their chemical and physical properties. To brindge this gap of knowledge\, we designed nanovehicles targeted to receptors of the main routes of transcytosis across endothelial barriers\, i.e. clathrin-\, caveolar\, and cell adhesion molecule (CAM)-mediated pathways (identified in our lab)\, and compared their BBB transport in cellular and animal models. Targeting these three routes resulted in transport across the endothelial lining\, whereas the CAM pathway was the most effective across a broad spectrum of carrier sizes and targeting valencies. This is reminiscent of the CAM function\, which contributes to transcellular leukocyte migration\, and it happened through a remodeling of the lipid composition of the endothelial plasmalemma and reorganization of the actin cytoskeleton. By understanding the biological regulation of this pathway\, we were able to optimize carrier design parameters to enhance BBB crossing. This needed a fine balance between the ability of carriers to bind to BBB receptors at the apical (circulation) surface and to detach from them at the basolateral (brain) side. As a result\, cargoes such as enzyme therapeutics for the treatment of neurological lysosomal disorders\, were delivered in an active form in the brain after intravenous administration in mouse models. Our current efforts aim to implement this strategy for the development of new therapeutics against other neurodegenerative conditions\, such as Parkinson’s disease. \n 
URL:https://ibecbarcelona.eu/event/ibec-seminar-silvia-muro-2/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar
ATTACH;FMTTYPE=image/jpeg:https://ibecbarcelona.eu/wp-content/uploads/2019/03/ibecfasterfuture1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20190322T100000
DTEND;TZID=Europe/Madrid:20190322T120000
DTSTAMP:20260425T121949
CREATED:20190319T101144Z
LAST-MODIFIED:20190322T085625Z
UID:65995-1553248800-1553256000@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Silvia Muro
DESCRIPTION:Spread the word!\nNest Friday we are glad to present to all those who are part of the IBEC community the IBEC FASTER FUTURE programme\, an initiative to accelerate our research in a collaborative way together with patients’ associations and hospitals. Everyone can be involved and we will comment the different ways to contribute to Faster Future. \nThis year\, we have added a new project led by Dr. Silvia Muro\, responsible for the Targeted therapeutics and nanodevices group\, related to Parkinson’s disease\, that affects millions of people around the world. \nIn this presentation\, Silvia Muro will talk about Enabling Delivery of Therapeutics Across the Blood-Brain Barrier for Treatment of Neurodegenerative Diseases. \nGet involved\, we count on you!\nEnabling Delivery of Therapeutics Across the Blood-Brain Barrier for Treatment of Neurodegenerative Diseases\nSilvia Muro\, IBEC Group Leader Targeted therapeutics and nanodevices / ICREA Research Professor\n \nAccessing the brain is key to study its function and pathology\, and for diagnostic and therapeutic purposes. Yet\, this remains a formidable challenge due to the blood-brain barrier (BBB). To overcome this obstacle\, new nanovehicles are being designed to cross this interface\, without much translational success. A prime obstacle is the lack of knowledge on the biological regulation of these devices\, as most efforts have been devoted to controling their chemical and physical properties. To brindge this gap of knowledge\, we designed nanovehicles targeted to receptors of the main routes of transcytosis across endothelial barriers\, i.e. clathrin-\, caveolar\, and cell adhesion molecule (CAM)-mediated pathways (identified in our lab)\, and compared their BBB transport in cellular and animal models. Targeting these three routes resulted in transport across the endothelial lining\, whereas the CAM pathway was the most effective across a broad spectrum of carrier sizes and targeting valencies. This is reminiscent of the CAM function\, which contributes to transcellular leukocyte migration\, and it happened through a remodeling of the lipid composition of the endothelial plasmalemma and reorganization of the actin cytoskeleton. By understanding the biological regulation of this pathway\, we were able to optimize carrier design parameters to enhance BBB crossing. This needed a fine balance between the ability of carriers to bind to BBB receptors at the apical (circulation) surface and to detach from them at the basolateral (brain) side. As a result\, cargoes such as enzyme therapeutics for the treatment of neurological lysosomal disorders\, were delivered in an active form in the brain after intravenous administration in mouse models. Our current efforts aim to implement this strategy for the development of new therapeutics against other neurodegenerative conditions\, such as Parkinson’s disease. \n 
URL:https://ibecbarcelona.eu/event/ibec-seminar-silvia-muro/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar
ATTACH;FMTTYPE=image/jpeg:https://ibecbarcelona.eu/wp-content/uploads/2019/03/ibecfasterfuture1.jpg
END:VEVENT
END:VCALENDAR